ClinicalTrials.gg
TerminatedNCT02750514FRACTION-LungUpdated Mar 22, 2021Results posted

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 interventional study of Nivolumab and Dasatinib in Advanced Cancer, sponsored by Bristol-Myers Squibb. Terminated at 50 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
The standard of care for the patient population changed and we were unable to accrue any longer.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Advanced Non Small Cell Lung Cancer (NSCLC)
  • (ECOG) Performance status of ≤ 1
  • of at least 3 months from most recent chemotherapy or immunotherapy treatment
  • Must have at least 1 lesion with

Exclusion criteria

Exclusion Criteria:

  • Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment
  • Subjects who need daily oxygen therapy
  • People with disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
295 participants (actual)

Study arms

  • Active comparator
    Nivolumab

    Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator

    Biological: Nivolumab

  • Experimental
    Nivolumab & Dasatinib

    Nivolumab in combination with Dasatinib

    Biological: Nivolumab · Drug: Dasatinib

  • Experimental
    Nivolumab & Relatlimab

    Nivolumab in combination with Relatlimab

    Biological: Nivolumab · Biological: Relatlimab

  • Experimental
    Nivolumab & Ipilimumab

    Nivolumab in combination with Ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab & BMS-986205

    Nivolumab in combination with BMS- 986205

    Biological: Nivolumab · Drug: BMS-986205

Interventions

  • BiologicalNivolumab

    Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

    Also known as: BMS-936558, MDX-1106, OPDIVO

  • Also known as: BMS-354825, SPRYCEL

  • BiologicalRelatlimab

    Also known as: BMS-986016

  • BiologicalIpilimumab

    Also known as: BMS-734016, Yervoy

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

    Time frame: From first dose to 2 years following last dose (up to 30 months)

  2. Duration of Response (DOR)

    DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

    Time frame: From first dose to 2 years following last dose (up to 30 months)

  3. Progression Free Survival Rate (PFSR) at 24 Weeks

    The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (\>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (\<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

    Time frame: From first dose to 24 weeks after first dose

Secondary outcomes

  1. Percentage of Participants Experiencing Adverse Events (AEs)

    This outcome measure describes the percentage of participants who experienced any grade, all causality AEs during the specified time frame

    Time frame: From first dose to 100 days following last dose

  2. Percentage of Participants Experiencing Serious Adverse Events (SAEs)

    This outcome measure describes the percentage of participants who experienced any grade, all causality SAEs during the specified time frame

    Time frame: From first dose to 100 days following last dose

  3. Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    This outcome measure describes the percentage of participants who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame

    Time frame: From first dose to 100 days following last dose

  4. Percentage of Participants Experiencing Death

    This outcome measure describes the percentage of participants who died (due to any cause) during the specified time frame

    Time frame: From first dose to up to 45 months following first dose

  5. Number of Participants Experiencing Laboratory Abnormalities in Hepatic Tests

    The following measurements will be considered laboratory abnormalities for hepatic tests: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal

    Time frame: From first dose to 100 days following last dose (approximately 9 months)

  6. Number of Participants Experiencing Laboratory Abnormalities in Thyroid Tests

    The following measurements will be considered laboratory abnormalities for thyroid tests: * TSH value \> ULN and * With baseline TSH value ≤ ULN * At least one T3/T4 test value \< LLN * Low TSH \< LLN and * With baseline TSH value ≥ LLN * At least one T3/T4 test value \> ULN TSH = thyroid stimulating hormone ULN=Upper Limit of Normal LLN=Lower Limit of Normal T3=Triiodothyronine T4=Thyroxine

    Time frame: From first dose to 100 days following last dose (approximately 9 months)

07

Results

Posted Mar 22, 2021
Limitations and caveats
This study was terminated early by sponsor for reasons unrelated to safety.

Participant flow

Track 1
Participant flow — Track 1
MilestoneNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Started404030
Completed132010
Not completed272020
Withdrew: Disease progression201010
Withdrew: Adverse event unrelated to study drug10000
Withdrew: Study drug toxicity41010
Withdrew: Participant request to discontinue10000
Withdrew: Other reasons10000
Track 2
Participant flow — Track 2
MilestoneNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Started982120
Completed30050
Not completed68270
Withdrew: Disease progression45250
Withdrew: Adverse event unrelated to study drug10000
Withdrew: Study drug toxicity12020
Withdrew: Participant withdrew consent01000
Track 3
Participant flow — Track 3
MilestoneNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Started04116180
Completed05120
Not completed03615160
Withdrew: Disease progression02413140
Withdrew: Adverse event unrelated to study drug01110
Withdrew: Study drug toxicity03010
Withdrew: Participant request to discontinue02000
Withdrew: Participant withdrew consent03100
Withdrew: Other reasons03000
Track 4
Participant flow — Track 4
MilestoneNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Started0530600
Completed020180
Not completed0510420
Withdrew: Study drug toxicity06050
Withdrew: Participant request to discontinue01010
Withdrew: Participant withdrew consent01000
Withdrew: Other reasons05030
Withdrew: Disease progression0330320
Withdrew: Adverse event unrelated to study drug05000
Withdrew: Death00010
Track 5
Participant flow — Track 5
MilestoneNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Started000043
Completed00000
Not completed000043
Withdrew: Disease progression000034
Withdrew: Adverse event unrelated to study drug00002
Withdrew: Study drug toxicity00002
Withdrew: Participant request to discontinue00003
Withdrew: Other reasons00002

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

Time frame:
From first dose to 2 years following last dose (up to 30 months)
Reported as:
Number · Percent of Participants
Objective Response Rate (ORR)
Percent of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Study Track 117.5 (7.3 to 32.8)25.0 (0.6 to 80.6)—0 (0.0 to 70.8)—
Study Track 20 (0.0 to 33.6)0 (0.0 to 33.6)0 (0.0 to 84.2)25.0 (5.5 to 57.2)—
Study Track 3—2.4 (0.1 to 12.9)0 (0.0 to 20.6)5.6 (0.1 to 27.3)—
Study Track 4—1.9 (0.0 to 10.1)—20.0 (10.8 to 32.3)—
Study Track 5————2.3 (0.1 to 12.3)
PrimaryDuration of Response (DOR)

DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

Time frame:
From first dose to 2 years following last dose (up to 30 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Study Track 112.81 (0.0 to NA)8.57 (NA to NA)———
Study Track 2———NA (NA to NA)—
Study Track 3—NA (NA to NA)—NA (NA to NA)—
Study Track 4—NA (NA to NA)—12.65 (8.7 to NA)—
Study Track 5————3.75 (NA to NA)
PrimaryProgression Free Survival Rate (PFSR) at 24 Weeks

The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (\>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (\<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Proportion of Participants
Progression Free Survival Rate (PFSR) at 24 Weeks
Proportion of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Study Track 10.302 (0.164 to 0.451)NA (NA to NA)—NA (NA to NA)—
Study Track 2NA (NA to NA)NA (NA to NA)NA (NA to NA)0.455 (0.167 to 0.707)—
Study Track 3—0.191 (0.079 to 0.340)NA (NA to NA)NA (NA to NA)—
Study Track 4—NA (NA to NA)—0.391 (0.265 to 0.514)—
Study Track 5————0.111 (0.036 to 0.235)
SecondaryPercentage of Participants Experiencing Adverse Events (AEs)

This outcome measure describes the percentage of participants who experienced any grade, all causality AEs during the specified time frame

Time frame:
From first dose to 100 days following last dose
Reported as:
Number · Percent of Participants
Percentage of Participants Experiencing Adverse Events (AEs)
Percent of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Percentage of Participants Experiencing Adverse Events (AEs)100.0100.0100.098.9100.0
SecondaryPercentage of Participants Experiencing Serious Adverse Events (SAEs)

This outcome measure describes the percentage of participants who experienced any grade, all causality SAEs during the specified time frame

Time frame:
From first dose to 100 days following last dose
Reported as:
Number · Percent of Participants
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
Percent of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Percentage of Participants Experiencing Serious Adverse Events (SAEs)57.153.861.158.160.5
SecondaryPercentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

This outcome measure describes the percentage of participants who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame

Time frame:
From first dose to 100 days following last dose
Reported as:
Number · Percent of Participants
Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Percent of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation14.323.65.611.814.0
SecondaryPercentage of Participants Experiencing Death

This outcome measure describes the percentage of participants who died (due to any cause) during the specified time frame

Time frame:
From first dose to up to 45 months following first dose
Reported as:
Number · Percent of Participants
Percentage of Participants Experiencing Death
Percent of ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
Percentage of Participants Experiencing Death57.155.766.746.262.8
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Hepatic Tests

The following measurements will be considered laboratory abnormalities for hepatic tests: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal

Time frame:
From first dose to 100 days following last dose (approximately 9 months)
Reported as:
Number · Participants
Number of Participants Experiencing Laboratory Abnormalities in Hepatic Tests
ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
ALT OR AST > 3XULN43153
ALT OR AST > 5XULN20032
ALT OR AST > 10XULN20012
ALT OR AST > 20XULN00011
TOTAL BILIRUBIN > 2XULN10023
Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN00022
Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN00022
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Thyroid Tests

The following measurements will be considered laboratory abnormalities for thyroid tests: * TSH value \> ULN and * With baseline TSH value ≤ ULN * At least one T3/T4 test value \< LLN * Low TSH \< LLN and * With baseline TSH value ≥ LLN * At least one T3/T4 test value \> ULN TSH = thyroid stimulating hormone ULN=Upper Limit of Normal LLN=Lower Limit of Normal T3=Triiodothyronine T4=Thyroxine

Time frame:
From first dose to 100 days following last dose (approximately 9 months)
Reported as:
Number · Participants
Number of Participants Experiencing Laboratory Abnormalities in Thyroid Tests
ParticipantsNivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205
TSH > ULN9163249
TSH > ULN WITH TSH <= ULN AT BASELINE691176
TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN43186
TSH < LLN530204
TSH < LLN WITH TSH >= LLN AT BASELINE510164
TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN31050

Adverse events

Collected over All cause mortality: from first dose to up to 45 months after first dose SAEs and AEs: from first dose to 100 days following last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Track 1 - Nivolumab22/40 (55%)24/40 (60%)38/40 (95%)
Track 1 - Nivolumab + Dasatinib2/4 (50%)2/4 (50%)4/4 (100%)
Track 1 - Nivolumab + Ipilimumab1/3 (33.3%)0/3 (0%)3/3 (100%)
Track 2 - Nivolumab6/9 (66.7%)4/9 (44.4%)9/9 (100%)
Track 2 - Nivolumab + Dasatinib4/8 (50%)5/8 (62.5%)7/8 (87.5%)
Track 2 - Nivolumab + BMS9860162/2 (100%)2/2 (100%)2/2 (100%)
Track 2 - Nivolumab + Ipilimumab6/12 (50%)5/12 (41.7%)12/12 (100%)
Track 3 - Nivolumab + Dasatinib20/41 (48.8%)17/41 (41.5%)38/41 (92.7%)
Track 3 - Nivolumab + BMS98601610/16 (62.5%)9/16 (56.3%)16/16 (100%)
Track 3 - Nivolumab + Ipilimumab9/18 (50%)10/18 (55.6%)17/18 (94.4%)
Track 4 - Nivolumab + Dasatinib33/53 (62.3%)33/53 (62.3%)50/53 (94.3%)
Track 4 - Nivolumab + Ipilimumab27/60 (45%)39/60 (65%)59/60 (98.3%)
Track 5 - Nivolumab + BMS98620527/43 (62.8%)26/43 (60.5%)41/43 (95.3%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventTrack 1 - NivolumabTrack 1 - Nivolumab + DasatinibTrack 1 - Nivolumab + IpilimumabTrack 2 - NivolumabTrack 2 - Nivolumab + DasatinibTrack 2 - Nivolumab + BMS986016Track 2 - Nivolumab + IpilimumabTrack 3 - Nivolumab + DasatinibTrack 3 - Nivolumab + BMS986016Track 3 - Nivolumab + IpilimumabTrack 4 - Nivolumab + DasatinibTrack 4 - Nivolumab + IpilimumabTrack 5 - Nivolumab + BMS986205
Atrial flutterCardiac disorders0/400/40/30/90/81/20/120/410/160/180/531/600/43
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/400/40/32/91/81/21/129/413/163/1819/5316/6013/43
PneumonitisRespiratory, thoracic and mediastinal disorders3/400/40/30/91/81/20/121/410/160/184/533/603/43
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/400/40/30/90/81/20/120/410/160/180/531/601/43
Pericardial effusionCardiac disorders3/401/40/30/90/80/20/120/410/160/180/531/600/43
PyrexiaGeneral disorders0/401/40/30/90/80/20/120/410/160/182/533/600/43
PneumoniaInfections and infestations2/401/40/31/90/80/20/121/410/162/180/533/601/43
Post procedural infectionInfections and infestations0/401/40/30/90/80/20/120/410/160/180/530/600/43
Pleural effusionRespiratory, thoracic and mediastinal disorders2/401/40/30/92/80/20/121/410/161/183/532/601/43
Oesophageal food impactionGastrointestinal disorders0/400/40/30/91/80/20/120/410/160/180/530/600/43
Most frequent other events
Showing 10 of 219
Most frequent other events
EventTrack 1 - NivolumabTrack 1 - Nivolumab + DasatinibTrack 1 - Nivolumab + IpilimumabTrack 2 - NivolumabTrack 2 - Nivolumab + DasatinibTrack 2 - Nivolumab + BMS986016Track 2 - Nivolumab + IpilimumabTrack 3 - Nivolumab + DasatinibTrack 3 - Nivolumab + BMS986016Track 3 - Nivolumab + IpilimumabTrack 4 - Nivolumab + DasatinibTrack 4 - Nivolumab + IpilimumabTrack 5 - Nivolumab + BMS986205
ConstipationGastrointestinal disorders9/403/43/30/91/80/23/129/411/162/1820/5318/6013/43
NauseaGastrointestinal disorders14/403/42/33/94/80/23/1216/413/164/1822/5318/6016/43
DyspnoeaRespiratory, thoracic and mediastinal disorders14/403/40/32/93/81/21/127/410/166/1821/5320/606/43
RashSkin and subcutaneous tissue disorders5/401/42/30/92/80/20/127/413/163/187/5310/603/43
FatigueGeneral disorders16/401/40/31/94/80/26/1219/415/168/1827/5330/6020/43
DiarrhoeaGastrointestinal disorders13/400/41/32/94/80/24/128/415/162/1820/5317/6011/43
AstheniaGeneral disorders5/402/40/32/91/80/20/124/410/160/1811/5311/601/43
Chest painGeneral disorders3/401/40/31/91/81/20/120/410/162/185/533/602/43
OedemaGeneral disorders0/402/40/30/90/80/20/121/410/160/184/531/602/43
PyrexiaGeneral disorders3/402/40/31/92/80/22/124/411/163/1810/5310/605/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205Total
Mean64.5 ± 10.2763.6 ± 9.2566.6 ± 9.1762.3 ± 9.0463.6 ± 7.8963.5 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)NivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205Total
Female213483821122
Male287095016173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205Total
Hispanic or Latino120519
Not Hispanic or Latino2565175827192
Unknown or Not Reported2337025994
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NivolumabNivolumab + DasatinibNivolumab + BMS986016Nivolumab + IpilimumabNivolumab + BMS986205Total
American Indian or Alaska Native000000
Asian2722316
Native Hawaiian or Other Pacific Islander000000
Black or African American0616619
White4285147826245
More than one race000000
Unknown or Not Reported5602215
08

Study locations

50 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of Southern California (USC)
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of Californa, Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
  • University of California San Diego
    San Diego, California 92122, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • University of Maryland - Marlene and Stewart Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber/Harvard Cancer Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Ce
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University, The Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89119, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Univ of NC Shool of Medicine
    Chapel Hill, North Carolina 27514, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Northwest Cancer Specialists
    Portland, Oregon 97225, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15217, United States
  • The West Clinic, P.C. d/b/a West Cancer Center
    Germantown, Tennessee 38138, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Sammons Cancer Center (Uso)
    Dallas, Texas 75246, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Us Oncology
    Tyler, Texas 75702, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • University of Washington-Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Local Institution
    Clayton, Victoria, Australia
  • Local Institution
    Salzburg, 5020, Austria
  • Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
  • University Of Ottawa - The Ottawa Hospital Cancer centre
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution
    Edmonton, T6G 1Z2, Canada
  • Local Institution
    Paris, 75005, France
  • Local Institution
    Toulouse, 31059, France
  • Local Institution
    Villejuif Cedex, 94805, France
  • Local Institution
    Milano, 20132, Italy
  • Local Institution
    Milan, 20141, Italy
  • Local Institution
    Rozzano, 20089, Italy
  • Local Institution
    Madrid, 28041, Spain
  • Local Institution
    Madrid, 28050, Spain
  • Local Institution
    Pamplona, 31008, Spain
  • Local Institution
    Lausanne, CH-1011, Switzerland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jan 2020, 44 months.

Results were first posted in Mar 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2016
First posted
Apr 25, 2016
StartActual
May 9, 2016
Primary completionActual
Jan 29, 2020
CompletionActual
Jan 29, 2020
Results first posted
Mar 22, 2021
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02750514
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
May 9, 2016
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020
Results posted
Mar 22, 2021
Last update
Mar 22, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dasatinib · Relatlimab · Ipilimumab · Linrodostat

Start the discussion